Therapy Resistance

One of the most critical challenges in oncology is therapy resistance, where cancer cells adapt to and evade the effects of treatments like chemotherapy, leading to treatment failure and disease progression. Resistance mechanisms often involve molecular changes that enable tumor survival, making it harder to eliminate cancer effectively.

The Role of ALDH1A3 in Resistance

Research has identified ALDH1A3 as a key player in therapy resistance:

• It promotes the survival of cancer stem cells (CSCs), which are highly resistant to chemotherapy and radiation.
• ALDH1A3-driven signaling pathways enhance tumor cell adaptability, allowing cancers to grow despite aggressive treatment regimens.

How Theranib Addresses This Challenge

Theranib Inc.’s innovative approach targets ALDH1A3 with its first-in-class inhibitor, VE3, designed to disrupt the mechanisms of therapy resistance:

• Inhibiting Cancer Stem Cells: VE3 specifically targets ALDH1A3-expressing CSCs, reducing their ability to survive treatment and drive tumor recurrence.
• Enhancing Therapy Efficacy: By sensitizing tumor cells to existing therapies, VE3 improves the effectiveness of chemotherapy and radiation.
• Precision-Driven Treatment: Biomarker diagnostics ensure VE3 is administered to patients with high ALDH1A3 levels, maximizing its impact while minimizing unnecessary exposure.

The Impact

By addressing therapy resistance at its core, Theranib’s ALDH1A3-targeted approach not only enhances treatment outcomes but also offers new hope for patients with aggressive, treatment-resistant cancers. This breakthrough represents a significant step forward in advancing personalized and effective cancer care.